Melike Bektaş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melike Bektaş has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Huseyin Arikan
Marmara Üniversitesi
2 shared publications - Adil Karaturna1 shared publication
- Ahmed Cihad Genç
Department of Internal Medicine, Sakarya Eğitim ve Araştırma Hastanesi, Adapazari, Turkey, Turkey (Türkiye)
1 shared publication - Ahmet Altaş
Department of Emergency, Faculty of Medicine, Health Sciences University, İzmir Tepecik Education and Research Hospital, İzmir, Türkiye
1 shared publication - Ahmet Bindal
Department of Anesthesiology and Reanimation, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye
1 shared publication - Ahmet Devehane1 shared publication
Latest Publications
- 31 March 2026
- Published by Academician Publishing
Olgularla Yoğun Bakım II
- 31 March 2026
- Published by Academician Publishing
- p. 311-322
Trombolitik Kontrendike Masif Pulmoner Embolide Embolektomi Olgusu
Bu bölüm, trombolitik tedavinin kontrendike olduğu masif pulmoner emboli (PE) olgusunda cerrahi embolektomi yaklaşımını, güncel literatür ve yoğun bakım perspektifi eşliğinde ele almaktadır. Pulmoner embolinin epidemiyolojisi, risk faktörleri, klinik bulguları ve ESC kılavuzlarına dayalı risk sınıflaması ayrıntılı biçimde sunulmakta; özellikle sağ ventrikül disfonksiyonu, biyobelirteçler ve hemodinamik instabilitenin prognozdaki rolü vurgulanmaktadır. Tanısal algoritmada CTPA, ekokardiyografi ve kritik hastada POCUS’un yeri tartışılmaktadır. Yüksek riskli PE’de organ desteği, oksijen tedavisi, sıvı yönetimi ve vazopresör kullanımı gibi yoğun bakım stratejileri açıklanmakta; antikoagülasyon ve fibrinoliz endikasyonları gözden geçirilmektedir. Trombolizin kontrendike olduğu veya başarısız kaldığı durumlarda cerrahi embolektomi, VA-ECMO ve kateter-yönlendirmeli tedaviler gibi alternatif reperfüzyon yöntemleri değerlendirilmiştir. Sunulan olgu, spinal cerrahi sonrası gelişen ve fibrinoliz uygulanamayan masif PE’de başarılı cerrahi embolektomi ile klinik iyileşmeyi göstermektedir. Bölüm, kritik PE yönetiminde multidisipliner yaklaşımın önemini vurgulamaktadır. This chapter presents the management of massive pulmonary embolism (PE) when thrombolytic therapy is contraindicated, focusing on a case treated with surgical embolectomy. Epidemiology, risk factors, and ESC-based risk stratification are reviewed, with particular emphasis on right ventricular dysfunction, biomarkers, and hemodynamic instability as key prognostic determinants. The diagnostic approach highlights the roles of CTPA, echocardiography, and point-of-care ultrasound in critically ill patients. Intensive care strategies—including oxygen support, fluid management, vasopressor use, and organ support—are discussed in the context of high-risk PE. The indications and limitations of anticoagulation and fibrinolysis are outlined, followed by alternative reperfusion strategies such as surgical embolectomy, VA-ECMO, and catheter-directed therapies. The presented case illustrates successful surgical management of massive PE in a patient with recent spinal surgery, where thrombolysis was contraindicated. The chapter underscores the importance of rapid risk stratification, timely reperfusion decisions, and a multidisciplinary PE response approach in critically ill patients.
- 31 March 2026
- Published by Academician Publishing
- p. 311-322
Trombolitik Kontrendike Masif Pulmoner Embolide Embolektomi Olgusu
Bu bölüm, trombolitik tedavinin kontrendike olduğu masif pulmoner emboli (PE) olgusunda cerrahi embolektomi yaklaşımını, güncel literatür ve yoğun bakım perspektifi eşliğinde ele almaktadır. Pulmoner embolinin epidemiyolojisi, risk faktörleri, klinik bulguları ve ESC kılavuzlarına dayalı risk sınıflaması ayrıntılı biçimde sunulmakta; özellikle sağ ventrikül disfonksiyonu, biyobelirteçler ve hemodinamik instabilitenin prognozdaki rolü vurgulanmaktadır. Tanısal algoritmada CTPA, ekokardiyografi ve kritik hastada POCUS’un yeri tartışılmaktadır. Yüksek riskli PE’de organ desteği, oksijen tedavisi, sıvı yönetimi ve vazopresör kullanımı gibi yoğun bakım stratejileri açıklanmakta; antikoagülasyon ve fibrinoliz endikasyonları gözden geçirilmektedir. Trombolizin kontrendike olduğu veya başarısız kaldığı durumlarda cerrahi embolektomi, VA-ECMO ve kateter-yönlendirmeli tedaviler gibi alternatif reperfüzyon yöntemleri değerlendirilmiştir. Sunulan olgu, spinal cerrahi sonrası gelişen ve fibrinoliz uygulanamayan masif PE’de başarılı cerrahi embolektomi ile klinik iyileşmeyi göstermektedir. Bölüm, kritik PE yönetiminde multidisipliner yaklaşımın önemini vurgulamaktadır. This chapter presents the management of massive pulmonary embolism (PE) when thrombolytic therapy is contraindicated, focusing on a case treated with surgical embolectomy. Epidemiology, risk factors, and ESC-based risk stratification are reviewed, with particular emphasis on right ventricular dysfunction, biomarkers, and hemodynamic instability as key prognostic determinants. The diagnostic approach highlights the roles of CTPA, echocardiography, and point-of-care ultrasound in critically ill patients. Intensive care strategies—including oxygen support, fluid management, vasopressor use, and organ support—are discussed in the context of high-risk PE. The indications and limitations of anticoagulation and fibrinolysis are outlined, followed by alternative reperfusion strategies such as surgical embolectomy, VA-ECMO, and catheter-directed therapies. The presented case illustrates successful surgical management of massive PE in a patient with recent spinal surgery, where thrombolysis was contraindicated. The chapter underscores the importance of rapid risk stratification, timely reperfusion decisions, and a multidisciplinary PE response approach in critically ill patients.
- Open Access
- 30 April 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (2) , 421-427
Characteristics and mortality determinants of COVID-19 patients undergoing hemodialysis
Background/aim: The COVID-19 infection, which started in Wuhan City, China, in December 2019, turned into a pandemic in a very short time, affecting mainly the elderly and those with serious chronic illnesses. COVID-19 infections have been observed to have a high mortality rate, especially in patients undergoing maintenance hemodialysis. Materials and methods: Forty-two patients over 18 years of age who underwent a maintenance hemodialysis program at our unit, who tested positive for COVID-19 by PCR from nasopharyngeal swabs, and/or who were observed to have disease-related signs in their CTs were included in the study. Results: In this study, 23 of 42 patients receiving hemodialysis support in our clinic were included. The median age was 67 years old (min: 35; max: 91 years), and all of our patients had primary hypertension and other comorbidities. Their clinical evaluation showed that dry cough (47.8%) and shortness of breath (47.8%) were the most common symptoms. Fever was less pronounced (30.4%). The median time from the onset of symptoms to hospitalization was 1 day (min: 0; max:), and the time from hospitalization to death was 18 days (min: 1; max: 22). Transfer from the inpatient ward to the ICU took a median of 7 days (min: 1; max: 13). Among the 23 patients, 3 died during follow-up, and 20 were discharged with full recovery. Baseline ferritin, procalcitonin levels, and CRP/albumin rates were higher, and neutrophil/lymphocyte levels were lower in patients who eventually died. In these patients, despite being nonsignificant, there were more diabetic patients, and the D-dimer levels were higher than 1000 ugFEU/L. Conclusion: The COVID-19 infection is associated with increased mortality in chronic kidney diseases patients. Despite being nonsignificant, there was a trend towards increased mortality in patient with diabetes, D-dimer levels >1000 ugFEU/L, higher ferritin and prokalsitonin levels, an increased CRP/albumin ratio, and a lower neutrophil/lymphocyte ratio.
- 30 April 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (2) , 421-427
Open AccessCharacteristics and mortality determinants of COVID-19 patients undergoing hemodialysis
Background/aim: The COVID-19 infection, which started in Wuhan City, China, in December 2019, turned into a pandemic in a very short time, affecting mainly the elderly and those with serious chronic illnesses. COVID-19 infections have been observed to have a high mortality rate, especially in patients undergoing maintenance hemodialysis. Materials and methods: Forty-two patients over 18 years of age who underwent a maintenance hemodialysis program at our unit, who tested positive for COVID-19 by PCR from nasopharyngeal swabs, and/or who were observed to have disease-related signs in their CTs were included in the study. Results: In this study, 23 of 42 patients receiving hemodialysis support in our clinic were included. The median age was 67 years old (min: 35; max: 91 years), and all of our patients had primary hypertension and other comorbidities. Their clinical evaluation showed that dry cough (47.8%) and shortness of breath (47.8%) were the most common symptoms. Fever was less pronounced (30.4%). The median time from the onset of symptoms to hospitalization was 1 day (min: 0; max:), and the time from hospitalization to death was 18 days (min: 1; max: 22). Transfer from the inpatient ward to the ICU took a median of 7 days (min: 1; max: 13). Among the 23 patients, 3 died during follow-up, and 20 were discharged with full recovery. Baseline ferritin, procalcitonin levels, and CRP/albumin rates were higher, and neutrophil/lymphocyte levels were lower in patients who eventually died. In these patients, despite being nonsignificant, there were more diabetic patients, and the D-dimer levels were higher than 1000 ugFEU/L. Conclusion: The COVID-19 infection is associated with increased mortality in chronic kidney diseases patients. Despite being nonsignificant, there was a trend towards increased mortality in patient with diabetes, D-dimer levels >1000 ugFEU/L, higher ferritin and prokalsitonin levels, an increased CRP/albumin ratio, and a lower neutrophil/lymphocyte ratio.